Intermediates in the reduction of the antituberculosis drug PA-824, (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine, in aqueous solution.

Intermediates in the reduction of the antituberculosis drug PA-824, (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine, in aqueous solution. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Intermediates in the reduction of the antituberculosis drug PA-824, (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine, in aqueous solution. Abstract Text:

The reduction chemistry of the new anti-tuberculosis drug PA-824, together with a more water-soluble analogue, have been investigated using pulse and steady-state radiolysis in aqueous solution. Stepwise reduction of these nitroimidazo-dihydrooxazine compounds through electron transfer from the CO(2) (-) species revealed that, unlike related nitroimidazoles, 2-electron addition resulted in the reduction of the imidazole ring in preference to the nitro group. In mildly acidic solution a nitrodihydroimidazo intermediate was formed, which was reduced further to the amine product. In both alkaline and neutral solution, an intermediate produced on 2-electron reduction was resistant to further reduction and reverted to parent compound on extraction or mass spectrometric analysis of the solution. The unusual reduction chemistry of these nitroimidazole compounds, exhibiting ring over nitro group reduction, is associated with alkoxy substitution in the 2-position of a 4-nitroimidazole. The unique properties of the intermediates formed on the reduction of PA-824 need to be considered as playing a possible role in its bactericidal action.

Intermediates in the reduction of the antituberculosis drug PA-824, (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine, in aqueous solution. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Intermediates in the reduction of the antituberculosis drug PA-824, (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine, in aqueous solution. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Organic & biomolecular chemistry

VOLUME: 6

Page Numbers: 1973-80

Journal Abbreviation: Org. Biomol. Chem.

ISSN: 1477-0520

DAY: 9

MONTH: 04

YEAR: 2008

Intermediates in the reduction of the antituberculosis drug PA-824, (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine, in aqueous solution. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101154995

Intermediates in the reduction of the antituberculosis drug PA-824, (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine, in aqueous solution. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Intermediates in the reduction of the antituberculosis drug PA-824, (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine, in aqueous solution. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Intermediates in the reduction of the antituberculosis drug PA-824, (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine, in aqueous solution.

AFFILIATION: Department of Chemistry, The University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand. r.anderson@auckland.ac.nz.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Org Biomol Chem

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Intermediates in the reduction of the antituberculosis drug PA-824, 6S-2-nitro-6-{4-trifluoromethoxybenzyloxy}-6,7-dihydro-5H-imidazo2,1-b1,3oxazine, in aqueous solution Related Publications

• ATP site-directed kinase inhibitors.
• An overview of the role of diet during the ageing process.
• Big and tall parents do not have more sons.
• Changes in cerebral hemodynamics in preterm infants with and without patent ductus arteriosus.
• Construction of YAC libraries with large inserts.
• Dysplasia epiphysialis punctata; report of a case and review of literature.
• Echinacea purpurea supplementation stimulates select groups of human gastrointestinal tract microbiota.
• Forum on research and scholarly activity.
• Gender And Age Related Changes In Strength And Submaximal Performance Outcomes For Individuals With CHF: 2240: Board #153 June 1 8:00 AM - 9:30 AM.
• Intermediates in the reduction of the antituberculosis drug PA-824, (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine, in aqueous solution.
• Percutaneous imaging-guided core breast biopsy: 5 years' experience in a community hospital.
• Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport.
• Phosphoinositide-3-kinases (PI3Ks): Combined Comparative Modeling and 3D-QSAR To Rationalize the Inhibition of p110alpha.
• Placement and management of long-term central venous access catheters and ports.
• Quality assurance program for peripheral blood mononuclear cell cryopreservation.
• Queuing up for quality. Boosting quality with electronic work queues.
• Retroperitoneal hemorrhage after percutaneous nephrostomy.
• Safety and Effectiveness of Progressive Resistance TVaining in Heart Failure Patients: 2242: Board #155 June 1 8:00 AM - 9:30 AM.
• Salivary mucin as related to oral Streptococcus mutans in elderly people.
• Synthesis and structure-activity relationships of soluble 8-substituted 4-(2-chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of the Wee1 and Chk1 checkpoint kinases.
• The global health and diagnostic (flow) cytometry--breakthroughs in HIV and tuberculosis.
• The who, what, when, why and how of professional negotiations for nurses.
• The who, what, when, why and how of professional negotiations for nurses.
• The who, what, when, why and how of professional negotiations for nurses.
• The who, what, when, why and how of professional negotiations for nurses.
• The who, what, when, why and how of professional negotiations for nurses.
• The who, what, when, why and how of professional negotiations for nurses.
• Use of the balloon on a guidewire as an adjunct to conventional angioplasty.
• Women's journey of recovery from sexual assault trauma: a grounded theory--part 1.
• Women's journey of recovery from sexual assault trauma: a grounded theory--part 2.